Health Canada's approval of a second Canadian-manufactured generic version of semaglutide — the active ingredient in Novo Nordisk's blockbuster Ozempic — is prompting immediate responses from major pharmacy chains and provincial drug benefit programmes, according to regulatory records published Saturday. The approval, the second generic nod for the diabetes and weight-loss drug within days, is expected to deepen price pressure on Novo Nordisk's Canadian operations and accelerate negotiations between generic manufacturers and provincial formulary bodies.

The new entrant joins Dr. Reddy's Laboratories' recently approved generic semaglutide, making Canada the only G7 nation with multiple approved lower-cost alternatives to Ozempic on the market. Health Canada officials noted the approvals reflect the agency's expedited review pathway for high-demand medications, particularly those addressing chronic conditions with significant public health burden.

Pharmacies including Shoppers Drug Mart and Rexall are expected to begin listing competitive pricing structures for the generics as early as this weekend, with analysts at RBC Capital Markets projecting that the retail price for a monthly course of semaglutide injections could fall by 30 to 40 percent within three months of full market entry. Provincial plans in Ontario and British Columbia have indicated readiness to fast-track formulary inclusion reviews for approved generics.

Novo Nordisk Canada released a statement reaffirming the clinical differentiation of its branded Ozempic and Wegovy products, citing proprietary delivery device technology and extensive long-term safety data. The Danish pharmaceutical giant has faced mounting pressure globally as generic and biosimilar GLP-1 approvals advance across multiple jurisdictions.

Health policy advocates welcomed the back-to-back approvals as a turning point for affordability of obesity and diabetes treatments in Canada. 'We are watching Canada become a genuine test case for how wealthy nations can broaden access to transformative medications without waiting a decade for patent cliffs,' said a spokesperson for the Canadian Diabetes Care Alliance. With the United States still several years away from comparable generic GLP-1 approvals, Canadian patients stand to benefit significantly from the competitive landscape now taking shape.